ProCE Banner Activity

CE / CME

Applying The Results of Practice-Changing Clinical Research To Patient Care in Hepatocellular Carcinoma

Text Module
In this interactive module, expert faculty use a case-based approach to discuss contemporary management of patients with advanced HCC.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: October 29, 2020

Expiration: October 28, 2021

No longer available for credit.

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Lilly

Target Audience

This program is intended for oncologists, nurse practitioners, clinical nurse specialists, pharmacists, and other allied health professionals who care for patients with HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explore the current status of predictive biomarkers for identification and selection of patients for novel therapies and emerging molecular/immunologic classifications that could inform future biomarker-enriched clinical trial design, enabling precision oncology care in HCC
  • Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
  • Review recent therapeutic advances and FDA approvals of novel systemic treatments (including targeted and immunotherapeutic agents) for patients with newly diagnosed and relapsed/refractory advanced HCC and integrate this information into clinical practice
  • Plan therapeutic strategies that optimize the selection/sequence of therapies to provide the best outcome for patients with HCC in the first-line setting and for patients with advanced HCC and treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy, taking into consideration the available clinical evidence, known agent toxicity/tolerability profiles, expert recommendations, and patient preferences
  • Assess the safety profiles of targeted therapies and checkpoint inhibitors used in the management of HCC
  • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable learners in their care

Program Director Disclosure

Program Director

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, CStone, Eisai, Lilly, Merck, Pfizer, and Roche/Genentech.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.v

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-119-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 29, 2020, through October 28, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to manage patients with HCC.